期刊文献+

直肠癌危险因素的配对病例对照研究 被引量:2

原文传递
导出
摘要 目的 探索直肠癌发病的主要危险因素,为直肠癌的防治提供科学依据.方法 采用1:1配对病例-对照研究方法 ,选择本院118名直肠癌病人和118名非肿瘤病人分别作为病例组和对照组,按照性别和年龄进行配对;应用条件logistic回归对研究变量进行分析.结果多因素分析结果显示癌症家族史、高脂肪饮食及常处于坐位状态为直肠癌发病的危险因素,经常体育锻炼和常吃蔬菜是直肠癌发病的保护因素.结论 直肠癌发病受生活饮食习惯、癌症家族史和体育锻炼的影响.
作者 封英娟
出处 《中国医师杂志》 CAS 2008年第12期-,共2页 Journal of Chinese Physician
  • 相关文献

参考文献10

二级参考文献37

  • 1陈坤,焦登鳌.人群大肠癌筛检数量化方法的应用研究[J].中华肿瘤杂志,1993,15(1):37-40. 被引量:15
  • 2赵宁,俞顺章,孙伟民.胃癌危险因素病例对照研究的Meta分析[J].数理医药学杂志,1996,9(2):160-162. 被引量:2
  • 3周伦,余海,郑树.杭州市大肠癌危险因素分析[J].浙江医科大学学报,1996,25(5):204-206. 被引量:10
  • 4李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量:869
  • 5Potter JD. Colorectal cancer: Molecules and populations [J]. J Natl Cancer Inst. 1999,91(11) :916.
  • 6Le Marchand L, Wilkens LR, Hankin JH, et al. A casecontrol study of diet and colorectal cancer in a multiethnic population in Hawaii (United States) : lipids and foods of animal origin[J]. Cancer Causes Control, 1997, 8(4) : 637.
  • 7Boutron- Ruault MC, Senesse P, Faivre J, et al. Foods as risk factors for colorectal cancer: a case-control study in Burgundy (France)[J]. Eur J Cancer Prey. 1999, 8(3): 229.
  • 8Vineis P, McMichael A. Interplay between heterocyclic amines in cooked meat and metabolic phenotype in the etiology of colon cancer[J]. Cancer Causes Control, 1996; 7(4) : 479.
  • 9World Cancer Research Fund in association with American Institute for Cancer Research. Food nutrition and the prevention of cancer: a global perspective. Menasha. WI1 American Institute for Cancer Research. 1997.
  • 10Gerhardsson - de - Verdier M, Hagman U, Peters RK, et al. Meat, cooking methods and colorectal cancer: a case- referent study in Stockholm[J]. Int J Cancer, 1991, 49(4) :520.

共引文献170

同被引文献17

  • 1彭芳,周志姣,朱建思.人结直肠癌侵袭及转移机制研究进展[J].医学临床研究,2006,23(8):1273-1275. 被引量:1
  • 2杨明,孙群.法莫替丁与凝血酶联合治疗新生儿应激性溃疡合并上消化道出血疗效观察[J].中国医师杂志,2006,8(11):1576-1577. 被引量:3
  • 3黄仁伦.应激性溃疡发生机制研究进展[J].国际医药卫生导报,2006,12(22):120-122. 被引量:31
  • 4Chmotherapy of metastasis colorectal cacer. Prescrire Int,2010,19 (109) :219-224.
  • 5Whyte S, Pandor A, Stevenson M, et al. Bevacizumab in combi- nation with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer. Health Technol Assess, 2010,14(suppl 2) : 47-53.
  • 6de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver me- tastasis: an international multi-institutional analysis of 1669 pa- tients. Ann Surg,2009,250 (3) :440-448.
  • 7Van Cutsem E, Rivers F, Berry S, et al. Safety and efficacy of first- line bevacizumab with FOLFOX, XELOX, FOLFIRI and fiuoropy- rimidines in metastatic eolorectal cancer:the BEAT study. Ann On- col,2009,20(11) :1842-1847.
  • 8Wong R,Cunningham D ,Barbachano Y,et al. A multicentre study of capecitabine,oxaliplatin plus bevacizumab as perioprative treatment of patients with poor-risk colorectal liver-only metastases not select- ed for upfront resection. Ann Onco1,2011,22(9) :2042-2048.
  • 9Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine,and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectalcancer. J Clin Oncol, 2008,26( 11 ) :1830-1836.
  • 10Hayashi M, Inoue Y, Komeda K, et al. ClinieopathologicaI anal- ysis of recurrence patterns and prognostic factors for survival after hepatectomy for eolorectal liver mctastasisl BMC Surg,2010,10( 27 ) : 27-38.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部